前列腺癌患者接种COVID-19疫苗后腋窝淋巴结对18F-rhPSMA-7.3 PET/CT的暂时性反应性摄取
回顾性分析233例已接种和41例未接种COVID-19疫苗的前列腺癌患者,评估18F-rhPSMA-7.3 PET/CT上疫苗相关淋巴结病(VAL)的患病率、时间反应和特征。VAL患病率为45%,接种后8周内SUVratio阳性(2.05 ± 0.17),此后显著下降(1.35 ± 0.09)并接近未接种组(1.1 ± 0.2)。
要点
- 接种COVID-19疫苗后8周内,18F-rhPSMA-7.3 PET/CT上腋窝淋巴结摄取增高常见,患病率45%。
- 8周后SUVratio显著下降并接近未接种组水平。
- 转移性腋窝淋巴结SUVratio很高(>11),可与疫苗相关摄取区分。
核心结论
- 接种COVID-19疫苗后,18F-rhPSMA-7.3在腋窝淋巴结中的摄取增高常见,且可持续8周,解读PET/CT时应考虑这一发现。
研究设计与样本
- 回顾性分析233例已接种和41例未接种COVID-19疫苗的经确诊前列腺癌患者,均接受18F-rhPSMA-7.3 PET/CT检查。
主要发现
- 18F-rhPSMA-7.3 PET上VAL患病率为45%。
- 末次COVID-19疫苗接种后8周内,SUVratio为阳性(2.05 ± 0.17);此后SUVratio显著下降(1.35 ± 0.09),接近未接种组(1.1 ± 0.2)。
- 转移性腋窝淋巴结的SUVratio很高(>11),视觉或半定量均可容易检出。
- 3例患者观察到疑似发生并随后确认腋窝淋巴结转移受累,SUVratio在4.0至6.6之间。
- SUVratio与淋巴结大小相关(r = 0.93,P < 0.0001),淋巴结大小与接种后时间相关(r = -0.88,P < 0.0008)。
临床怎么用
- 原文结论指出,解读18F-rhPSMA-7.3 PET/CT检查时应考虑接种COVID-19疫苗后腋窝淋巴结摄取增高可持续8周这一发现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccine-associated lymphadenopathy (VAL) is a common finding on 18F-FDG PET/CT examinations after coronavirus disease 2019 (COVID-19) vaccination. However, data regarding VAL on 18F-rhPSMA-7.3-ligand PET are currently lacking. This study assesses the prevalence, temporal response to vaccination, and characteristics of VAL. Methods: Two hundred thirty-three consecutive vaccinated and 41 unvaccinated patients with confirmed prostate cancer who underwent 18F-rhPSMA-7.3 PET/CT were retrospectively analyzed. Size and uptake of the axillary lymph nodes were measured. Ratios of SUVmax of ipsilateral to contralateral axillary lymph node (SUVratio) were determined. The characteristics of SUVratio in respect to the duration of PSMA avidity in the axillary lymph node after COVID-19 vaccination was analyzed. Results: The prevalence of VAL on 18F-rhPSMA-7.3 PET was 45%. Up to a period of 8 wk after the last COVID-19 vaccination, SUVratio was positive (2.05 ± 0.17). Thereafter, SUVratio dropped significantly (1.35 ± 0.09) and approached the value of unvaccinated group (1.1 ± 0.2). SUVratio of metastatic axillary lymph nodes was very high (>11) and can be easily detected visually or semiquantitatively. In 3 patients, we observed suspected development and consecutively confirmed involving metastasis of axillary lymph node with SUVratio between 4.0 to 6.6. Correlation between SUVratio and lymph node size (r = 0.93, P < 0.0001) and lymph node size and duration after vaccine (r = -0.88, P < 0.0008) was found. Conclusion: Increased uptake of the PSMA ligand 18F-rhPSMA-7.3 by axillary lymph nodes is common after COVID-19 vaccination and can persist for 8 wk. This finding should be considered in the interpretation of 18F-rhPSMA-7.3 PET/CT examinations.
引用
- Notohamiprodjo S, Eiber M, Lohrmann C, et al. Temporary Reactive Response of Axillary Lymph Nodes to COVID-19 Vaccination on 18F-rhPSMA-7.3 PET/CT in Patients with Prostate Cancer. J Nucl Med. 2022. PMID: 35241484. doi:10.2967/jnumed.121.263758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。